000			03981nam a22004335i 4500
999			_c347254 _d347254 _x1
001			347254
003			ES-MaUEC
005			20230102120726.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			211013s2021 sz | s |||| 0|eng d
020			_a9783030393304
024	7		_a10.1007/978-3-030-39330-4 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aR726.7 _b2021 EB
100	1		_aPowell, Lynda H. _eautor _4aut _4http://id.loc.gov/vocabulary/relators/aut _9681399
245	1	0	_aBehavioral Clinical Trials for Chronic Diseases : _bScientific Foundations _cby Lynda H. Powell, Kenneth E. Freedland, Peter G. Kaufmann
250			_aFirst edition 2021
264		1	_aCham _bSpringer International Publishing _c2021
300			_a1 recurso en línea (XVIII, 314 páginas) _b40 ilustraciones, 22 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_aarchivo de texto _bPDF
490	0		_aBehavioral Science and Psychology (SpringerNature-41168)
490	0		_aBehavioral Science and Psychology (SpringerNature-43718)
505	0		_aIntroduction: the window of opportunity -- A selected history of randomized behavioral clinical trials: what we learned -- A clinically significant problem and a clincially significant benefit -- The process of developing a behavioral treatment for chronic disease -- The hypothesized pathway from behavioral treatment to chronic disease -- Equipoise, blinding, and investigator discipline -- Sensitivity to diversity -- Protection of randomization -- Choice of appropriate control group -- Readiness to conduct a behavioral randomized clinical trial -- Concluding remarks.
520	3		_aThis is the first comprehensive guide to the design of behavioral randomized clinical trials (RCT) for chronic diseases. It includes the scientific foundations for behavioral trial methods, problems that have been encountered in past behavioral trials, advances in design that have evolved, and promising trends and opportunities for the future. The value of this book lies in its potential to foster an ability to "speak the language of medicine" through the conduct of high-quality behavioral clinical trials that match the rigor commonly seen in double-blind drug trials. It is relevant for testing any treatment aimed at improving a behavioral, social, psychosocial, environmental, or policy-level risk factor for a chronic disease including, for example, obesity, sedentary behavior, adherence to treatment, psychosocial stress, food deserts, and fragmented care. Outcomes of interest are those that are of clinical significance in the treatment of chronic diseases, including standard risk factors such as cholesterol, blood pressure, and glucose, and clinical outcomes such as hospitalizations, functional limitations, excess morbidity, quality of life, and mortality. This link between behavior and chronic disease requires innovative clinical trial methods not only from the behavioral sciences but also from medicine, epidemiology, and biostatistics. This integration does not exist in any current book, or in any training program, in either the behavioral sciences or medicine.
988			_aSpringer_Psychology_2021
650		7	_2embne _9146219 _aTerapia de conducta _xInvestigación
650		7	_2embne _9151368 _aEnfermedades crónicas _xTratamiento
700	1		_aFreedland, Kenneth E. _eautor _4aut _4http://id.loc.gov/vocabulary/relators/aut _9681400
700	1		_aKaufmann, Peter G. _eautor _4aut _4http://id.loc.gov/vocabulary/relators/aut _9681401
776	0	8	_iPrinted edition: _z9783030393281
776	0	8	_iPrinted edition: _z9783030393298
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-39330-4 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b01/2022 _dz _esc _zSI